BPC-157: What the Evidence Actually Shows

BPC-157 is a synthetic peptide of 15 amino acids. It is widely promoted online for healing tendons, ligaments, muscles and the gut. Those claims rest mainly on studies in rats. They have not been confirmed by controlled trials in people.

This article sets out what each kind of evidence shows, what it does not show, and where BPC-157 stands with regulators, keeping the three separate.

What BPC-157 is

The name stands for “Body Protection Compound”. It was first described in 1993 as a fragment of a protein reported in gastric juice. That name is a laboratory label. It says nothing about whether the substance protects the body in humans.

BPC-157 is sometimes called a “naturally occurring gastric peptide”. The substance studied and sold is made synthetically, and the FDA notes that BPC-157 is a common name rather than an official non-proprietary name.

It is not an ingredient of any approved medicine and is not included in the European, Japanese or International pharmacopoeias (FDA, July 2026). See What Are Peptides?

The claims and the evidence behind them

Claim commonly made online	Type of evidence available	What it shows
Heals tendons, ligaments and muscle	Animal studies, mainly rats	Faster healing in experimental injury models. Not tested in controlled human trials.
Repairs the gut, treats inflammatory bowel disease	Animal studies; one small human trial reported only as a meeting abstract	Protective effects on induced lesions in rats. The human ulcerative colitis trial did not show a clear difference from placebo.
Relieves joint pain	One retrospective telephone survey of 16 people	Self-reported improvement, without a control group or validated measures
Treats bladder pain (interstitial cystitis)	One uncontrolled study of 12 women	Self-reported improvement, without a control group
Safe in humans	Two people given intravenous infusions; small short studies	No serious adverse events reported, but data far too limited to characterize safety
“Accelerates recovery” in general	Anecdotal reports	Not evidence of effect

Similar evidence gaps apply to TB-500, often sold alongside it.

Laboratory and animal research

Most of what is known comes from rodent studies. These describe:

faster healing of experimentally injured tendons, ligaments, muscle and bone;
protection against gastric, intestinal and liver lesions induced by various chemical challenges;
proposed mechanisms, including increased expression of growth factors, reduced inflammatory signaling, formation of new blood vessels (angiogenesis) and effects on nitric oxide.

A 2025 systematic review from an orthopedic sports-medicine perspective identified 36 eligible studies: 35 preclinical and one clinical (Vasireddi et al., HSS J 2025).

When the FDA reviewed the evidence for its July 2026 advisory committee, it noted several limitations:

dose–response relationships have not been established;
pharmacological studies have been limited to rodents;
BPC-157’s molecular targets have not been identified, and its mechanism of action is unknown.

Where the research comes from. Most published BPC-157 research comes from one research group. In a PubMed search on September 30, 2026, 174 of 226 records indexed for BPC-157 listed the same senior investigator (P. Sikirić) as an author. This does not make the findings wrong. Independent replication, however, is one of the main ways science establishes that a result is robust, and it remains limited here.

Animal results often fail to translate to humans, for several reasons:

Models: injury models in rats differ from human injuries.
Doses and routes: those studied are not the ones used by people buying BPC-157 online.
Pharmacokinetics: after a single intravenous dose, the half-life was about 5 minutes in dogs and 15 minutes in rats (FDA summary of He et al. 2022). How the substance behaves after oral, nasal or subcutaneous use in humans is unknown.

Human evidence

The FDA’s July 2026 review summarized all the human studies it identified.

Study	Participants	What was done
Healthy volunteers, rectal enema, up to 8 days	24 healthy people	Rectal enema
Ulcerative colitis trial, two weeks	Around 26 people receiving BPC-157	Rectal enema; reported only as a meeting abstract
Knee pain, retrospective	17 people	Injection into the knee
Interstitial cystitis, pilot	12 women	Injection into the bladder wall
Intravenous infusion, pilot	2 healthy adults	Intravenous infusion

A few details matter:

Ulcerative colitis. The randomized trial in 53 people did not show a statistically clear difference from placebo in disease activity. It is available only as a meeting abstract, which lacks key methodological details (FDA, July 2026).
Knee pain. The study was a retrospective chart review with telephone follow-up. It used no validated outcome measures and had no control group (Lee and Padgett, Altern Ther Health Med 2021).
Interstitial cystitis. Participants reported symptom resolution, but the study had no control group and was not blinded (Lee et al., Altern Ther Health Med 2024).
Intravenous pilot. Two adults received infusions without notable adverse findings. Two people cannot establish safety (Lee and Burgess, Altern Ther Health Med 2025).

The FDA noted that safety monitoring in most studies was unclear, and that no study gave BPC-157 by the oral, subcutaneous, nasal or transdermal routes commonly used by people buying it online. An early-phase safety study registered in 2015 (NCT02637284) has no posted results.

Two new trials were registered in 2026: a placebo-controlled trial in acute hamstring strain (NCT07437547, recruiting) and a study after rotator cuff surgery (NCT07803250, not yet recruiting). They may eventually provide the first controlled data in musculoskeletal injury.

Why anecdotes are not evidence

Online accounts of rapid recovery are common. They cannot separate the effect of BPC-157 from other explanations:

the natural healing of many injuries over time;
the placebo effect;
other treatments used at the same time, such as rest, physiotherapy or other substances;
the tendency for positive experiences to be shared more than neutral or negative ones.

That is why controlled trials exist. The absence of controlled evidence does not prove that BPC-157 is ineffective. It means its effects in humans are unknown.

Safety: what is known and unknown

Human data. There are not enough to characterize BPC-157’s safety. The FDA stated in July 2026 that there is “insufficient clinical safety information to characterize the safety profile” of BPC-157.

Specific FDA concerns.

Immunogenicity. As a peptide given by injection or nasally, it may provoke an immune response, potentially amplified by aggregation and peptide-related impurities.
Animal toxicity. In 28-day toxicity studies in rats and dogs, the FDA identified signals potentially related to blood clotting and the liver. No longer-term studies were available.
Characterization. It judged the nominated forms of BPC-157 “not well-characterized” from a physicochemical perspective.

Adverse event reports. The FDA retrieved three reports involving BPC-157:

redness and swelling at the injection site;
shortness of breath leading to an emergency visit;
skin and gum darkening that recurred when the product was taken again.

Whether BPC-157 caused these effects could not be determined.

Regulatory status

United States. BPC-157 is not an approved drug. Its status in pharmacy compounding has changed during 2026, and three separate points need to be kept distinct:

Category 2 (until April 2026). The FDA had placed BPC-157 in “Category 2”, substances nominated for compounding that may present significant safety risks.
Removal from Category 2 (April 2026). The FDA removed BPC-157 from Category 2 after the underlying nominations were withdrawn. This did not constitute an FDA finding that BPC-157 is safe or effective. The FDA’s web page still lists BPC-157 among substances “nominated but withdrawn”, together with its concerns about immunogenicity, peptide-related impurities, characterization of the active ingredient, and the absence or scarcity of safety data in humans.
Advisory committee review (July 2026). On July 23, 2026 the FDA’s Pharmacy Compounding Advisory Committee considered whether BPC-157 should be added to the “503A Bulks List”, the list of substances that pharmacies may use to compound medicines for individual patients. The use under review was ulcerative colitis. FDA reviewers recommended that it not be added, citing:
- poor characterization;
- limited information on historical use;
- insufficient safety data;
- insufficient evidence of effectiveness;
- the availability of approved treatments.

Advisory committee advice is not binding on the FDA. As of September 2026 we found no final FDA decision; any addition to the list would require further regulatory steps.

Being considered for the 503A Bulks List, or even being placed on it, is not the same as approval of BPC-157 as a medicine. The list concerns whether pharmacies may compound with a substance. It does not involve a finding that the substance is safe and effective for any condition.

United Kingdom. BPC-157 is not an authorized medicine in the UK, and no UK product containing it is authorized. The MHRA has warned about, and seized, unlicensed “peptide products” sold for self-injection, including in 2026 enforcement operations.

Sport. WADA lists BPC-157 under S0, non-approved substances. It is prohibited at all times for athletes subject to the World Anti-Doping Code.

“Research use only” products

BPC-157 is widely sold online as a powder or pre-mixed injection labeled “for research use only” or “not for human consumption”.

No control over contents. Such products are not medicines. Nothing guarantees their identity, purity, sterility or dose.
No evidence behind their use. The research described above was carried out with specific preparations under study conditions, and does not validate these products.

See What Are Peptides?

Frequently asked questions

Is BPC-157 approved?

No. It is not an approved medicine in the UK or US, and according to the FDA it is not a component of an approved product in any country.

Does BPC-157 heal tendons or injuries?

This has been shown in animal studies but not in controlled human trials. A randomized trial in hamstring injury began recruiting in 2026.

Is BPC-157 safe?

Its safety in humans has not been established. The FDA considers the available human safety information insufficient and has identified potential immunogenicity, impurity and characterization concerns, and signals in short animal toxicity studies.

Did the FDA approve BPC-157 in 2026?

No. It was removed from Category 2 in April 2026 because the nominations were withdrawn. That was not a finding of safety or effectiveness. In July 2026 an FDA advisory committee considered whether it should be placed on the compounding list; FDA reviewers recommended against. As of September 2026 we found no final FDA decision, and even a listing would not be a drug approval.

Is BPC-157 legal in the UK?

It is not an authorized medicine in the UK. Selling or supplying unlicensed medicines for human use is regulated, and the MHRA has taken enforcement action against unlicensed peptide products.

Can athletes use BPC-157?

No. It is on WADA’s prohibited list under non-approved substances.

In summary

BPC-157 has an extensive animal literature, largely from one research group, and almost no controlled human evidence. The claims made for it online go well beyond what has been shown. In 2026 it was removed from the FDA’s Category 2 and reviewed by an FDA advisory committee, but neither step was a regulatory finding that it is safe or effective. Until controlled human trials report, the honest answer to “does BPC-157 work in people?” is that we do not know.

Sources and further reading

US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (web page, content current as of April 22, 2026). Lists BPC-157 among “bulk drug substances nominated but withdrawn”, with FDA’s stated concerns.
US Food and Drug Administration. Pharmacy Compounding Advisory Committee, 23–July 24, 2026: meeting page, questions, and FDA presentations (BPC-157-related bulk drug substances: evaluation and recommendation). Source of the human-study summary, pharmacokinetic and toxicology data, adverse event reports and FDA recommendation.
US Food and Drug Administration. Bulk drug substances used in compounding under section 503A (web page).
World Anti-Doping Agency. Prohibited List, section S0 (non-approved substances).
MHRA / GOV.UK. Enforcement releases on unlicensed weight-loss and peptide products, 2026.
ClinicalTrials.gov. NCT02637284 (PCO-02 safety and pharmacokinetics trial, 2015; no posted results); NCT07437547 (BPC-157 for acute hamstring strain; recruiting); NCT07803250 (BPC-157 after rotator cuff repair; not yet recruiting).
Vasireddi N, et al. Emerging use of BPC-157 in orthopedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495. doi:10.1177/15563316251355551
Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13.
Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12–17.
Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20–24.

This article is educational and does not constitute personalized treatment advice. Treatment decisions depend on individual circumstances and professional assessment.